Parker Waichman LLP

FDA Reviewing Stalevo for Cardiac Side Effects

The Food & Drug Administration (FDA) in conducting a safety review of the Parkinson’s disease drug Stalevo. In a notice posted to its Web site, the agency said it is evaluating clinical trial data that suggest patients taking Stalevo may be at an increased risk for cardiovascular events such as heart attacks and strokes compared […]

The Food & Drug Administration (FDA) in conducting a safety review of the Parkinson’s disease drug <"https://www.yourlawyer.com/practice_areas/defective_drugs">Stalevo. In a notice posted to its Web site, the agency said it is evaluating clinical trial data that suggest patients taking Stalevo may be at an increased risk for cardiovascular events such as heart attacks and strokes compared to patients taking another Parkinson’s drug known as Sinemet.

Stalevo is a combination of carbidopa/levodopa and entacapone, while Sinemet contains only carbidopa/levodopa. Entacapone is also available as a single ingredient product (sold under the brand name Comtan) to be always administered in association with carbidopa/levodopa.

According to the FDA, it is estimated that 154,000 patients received prescription for Stalevo from its approval in June 2003 through October 2009.

The FDA decided to conduct a safety review after a meta-analysis called the Stalevo Reduction In Dyskinesia Evaluation – Parkinson’s Disease, or STRIDE-PD, found a small increased risk of cardiovascular events in subjects taking Stalevo, according to the FDA. STRIDE-PD combined the cardiovascular-related findings from 15 clinical trials comparing Stalevo to carbidopa/levodopa.

Based on those findings, the FDA conducted a meta-analysis that combined the cardiovascular findings from 15 clinical trials in approximately 4,800 patients comparing entacapone/carbidopa/levodopa to carbidopa/levodopa without entacapone. A composite endpoint of myocardial infarction, stroke, and cardiovascular death was used to represent cardiovascular events. Twenty-seven cardiovascular events were reported in the entacapone/carbidopa/levodopa group compared to 10 in the carbidopa/levodopa group. This resulted in a relative risk of 2.46. When the STRIDE-PD trial was removed from the analysis, the relative risk was 1.67.

The FDA said it has not yet concluded that Stalevo increases the risk of heart attack, strokes, or cardiovascular death. The agency said healthcare professionals should regularly evaluate the cardiovascular status of patients who are taking Stalevo, especially if they have a history of cardiovascular disease. Patients should not stop taking Stalevo unless told to do so by their healthcare professional.

The FDA said it is exploring additional ways to assess whether Stalevo increases the risk of cardiovascular events, and will update the public when its review is complete.

What Our Clients Say About Us
We have worked with thousands of clients and we appreciate them and their positive reviews. Here are just a few recent client reviews...
5 Star Reviews 150
I would like to extend my gratitude to both Julie Trinidad and Marianne Gallizzi. They are part of a great team in Parker Waichman. I appreciate the time and effort you took to answer all of my questions.
Karyna Minchala
5 years ago
5 Star Reviews 150
I'm very satisfied with the service I received
Karen Jeffrey
3 years ago
5 Star Reviews 150
Edward Mooney
6 years ago

Why Choose Us to Help You?

We Take Care of Everything
Your situation is stressful enough: Let us take on the deadlines, paperwork, investigation, and litigation. We'll handle every detail so you don't have to worry.
No Recovery = No Legal Fees
We work on a contingency-fee basis, meaning that we only get paid from a portion of your settlement or jury award. If you don't get compensation, you owe us nothing.
Decades of Experience
Your situation is stressful enough: Let us take on the deadlines, paperwork, investigation, and litigation. We'll handle every detail so you don't have to worry.
Respected by Our Peers
Judges, insurance adjusters, and fellow attorneys all speak highly of our skills, and we've earned numerous accolades, including a flawless rating from AVVO.
We Have Many Locations To Serve You
We have the experience and the skilled litigators to win your case. Contact us and speak with a real attorney who can help you.
Long Island – Nassau
Parker Waichman LLP
6 Harbor Park Drive
Port Washington, NY 11050
Long Island – Suffolk
Parker Waichman LLP
201 Old Country Road – Suite 145
Melville, NY 11747
New York
Parker Waichman LLP
59 Maiden Lane, 6th Floor
New York, NY 10038
Queens
Parker Waichman LLP
118-35 Queens Boulevard, Suite 400
Forest Hills, NY 11375
Brooklyn
Parker Waichman LLP
300 Cadman Plaza West
One Pierrepont Plaza, 12th Floor
Brooklyn, NY 11201
New Jersey
Parker Waichman LLP
80 Main Street, Suite 265
West Orange, NJ 07052
Florida
Parker Waichman LLP
27299 Riverview Center Boulevard
Suite 108
Bonita Springs, FL 34134
Nationwide Service
Parker Waichman LLP
59 Maiden Lane, 6th Floor
New York, NY 10038